PMID- 38348139
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240214
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 18
DP  - 2024
TI  - Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from 
      Prior Pharmacotherapy: A Retrospective Chart Review.
PG  - 409-422
LID - 10.2147/OPTH.S442940 [doi]
AB  - INTRODUCTION: Latanoprostene bunod 0.024% (LBN, Vyzulta((R))) is a nitric 
      oxide-donating prostaglandin analog (PGA). We investigated the real-world 
      efficacy and safety of LBN in patients with open-angle glaucoma (OAG) or ocular 
      hypertension (OHT) who switched their existing intraocular pressure 
      (IOP)-lowering treatment(s) to LBN. METHODS: This non-interventional, multicenter 
      (United States), retrospective chart review included patients aged >/=18 years with 
      OHT and/or mild-to-moderate OAG diagnoses taking 1-2 IOP-lowering treatments at 
      the time of switch to LBN (index visit). Chart-extracted data included 
      demographics, diagnoses, IOP and ocular assessments, other IOP-lowering 
      treatments, adverse events (AEs), and reasons for discontinuation. The main study 
      outcome was IOP change from the index visit to each of the next 2 chart-recorded 
      follow-up visits. Analysis groups included the overall dataset and 2 subgroups of 
      patients switched from PGA therapy to LBN: "PGA-all" subgroup [all patients 
      previously on a PGA with/without another IOP-lowering product] and 
      "PGA-monotherapy" subgroup [patients previously on a PGA alone]). Additional 
      ocular outcomes (eg, visual acuity) were examined, if available. RESULTS: The 
      overall dataset included 49 patients (46 had OAD alone, 2 had OHT alone, and 1 
      had both). The PGA-all subgroup and PGA-monotherapy subgroups had 41 and 32 
      patients, respectively. Switching to LBN led to a ~25% IOP reduction from the 
      index visit to Visit 1 that was sustained at Visit 2. IOP findings in the PGA-all 
      and PGA-monotherapy subgroups were consistent with the overall dataset. No 
      meaningful changes in other ocular outcomes were found. Of 14 ocular AEs, 3 were 
      recorded as such (mild in severity, considered unrelated to treatment), and 11 
      were identified through review of interval ocular histories (no 
      severity/relatedness information); none led to discontinuation. CONCLUSION: In 
      this short-term retrospective chart review of mild-to-moderate OAG/OHT, switching 
      prior IOP-lowering therapy to LBN produced an additional ~25% IOP reduction and 
      appeared to be well tolerated.
CI  - (c) 2024 Okeke et al.
FAU - Okeke, Constance O
AU  - Okeke CO
AD  - Virginia Eye Consultants/CVP, Norfolk, VA, USA.
FAU - Cothran, Nora Lee
AU  - Cothran NL
AUID- ORCID: 0009-0007-1645-1796
AD  - The Eye Institute of West Florida, Largo, FL, USA.
FAU - Brinkley, Desirae A
AU  - Brinkley DA
AD  - Eye Specialty Group, Memphis, TN, USA.
FAU - Rahmatnejad, Kamran
AU  - Rahmatnejad K
AD  - Eastern Virginia Medical School, Norfolk, VA, USA.
FAU - Rodino, Frank J
AU  - Rodino FJ
AD  - Churchill Outcomes Research, Red Bank, NJ, USA.
FAU - Deom, James E
AU  - Deom JE
AD  - Hazleton Eye Specialists, Hazle Township, PA, USA.
LA  - eng
PT  - Journal Article
DEP - 20240207
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC10859762
OTO - NOTNLM
OT  - IOP
OT  - LBN
OT  - OAG
OT  - OHT
OT  - PGA
OT  - intraocular pressure
OT  - latanoprostene bunod
OT  - ocular hypertension
OT  - open-angle glaucoma
OT  - prostaglandin analog
COIS- Constance O. Okeke and Nora Lee Cothran report serving as consultants, 
      researchers, and speakers for Bausch + Lomb. Nora Lee Cothran reports personal 
      fees from Aerie, Alcon, Allergan/ AbbVie, Glaukos, Sight Sciences, outside the 
      submitted work. Frank J. Rodino is an employee of Churchill Outcomes Research 
      that supported the study. James E. Deom reports serving as a consultant for 
      Bausch + Lomb. Desirae A. Brinkley and Kamran Rahmatnejad have no conflicts to 
      report.
EDAT- 2024/02/13 06:44
MHDA- 2024/02/13 06:45
PMCR- 2024/02/07
CRDT- 2024/02/13 03:43
PHST- 2023/10/19 00:00 [received]
PHST- 2024/01/15 00:00 [accepted]
PHST- 2024/02/13 06:45 [medline]
PHST- 2024/02/13 06:44 [pubmed]
PHST- 2024/02/13 03:43 [entrez]
PHST- 2024/02/07 00:00 [pmc-release]
AID - 442940 [pii]
AID - 10.2147/OPTH.S442940 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2024 Feb 7;18:409-422. doi: 10.2147/OPTH.S442940. eCollection 
      2024.